Author details
Author Nancy Thiry |
Available item(s) by this author (135)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II / Marc Arbyn / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II : Update on HPV primary screening - Synthesis [printed text] / Marc Arbyn, Author ; Annemie Haelens, Author ; Anja Desomer, Author ; Freija Verdoodt, Author ; Nancy Thiry, Author ; Julie Francart, Author ; Germaine Hanquet, Author ; Jo Robays, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2015 . - 27 p. : ill;, ; A4. - (KCE Reports. Health Technology Assessment (HTA); 238Cs) .
ISSN : D/2015/10.273/16 : € 0,00
Study n°2013-25_HTA_HPV_DNA_Testing
Languages : English (eng)
Descriptors: Classification
WP 480 Cervix Uteri. Cervix Diseases -- Neoplasms
Indexation
Papillomavirus, Human ; 2013-25 ; Mass Screening ; R238 ; Uterine Cervical Neoplasms ; Vaginal SmearsContents note: FOREWORD 1 -- ABSTRACT 2 -- SYNTHESIS 4 -- 1. INTRODUCTION 6 -- 1.1. BACKGROUND 6 -- 1.1.1. Incidence 6 -- 1.1.2. Mass screening 6 -- 1.1.3. Caused by HPV 6 -- 1.1.4. Pap test 6 -- 1.1.5. HPV test 7 -- 1.2. THE PROBLEM ADDRESSED BY THIS REPORT. 7 -- 2. FINDINGS 8 -- 2.1. WHAT IS THE OPTIMAL SCREENING ALGORITHM FOR CERVICAL CANCER SCREENING 8 -- 2.1.1. Update on accuracy of HPV vs. cytology screening 8 -- 2.1.2. Efficacy of HPV-based compared to cytology-based screening 8 -- 2.1.3. Clinically validated HPV assays 9 -- 2.1.4. Screening interval: low risk of cervical pre-cancer and cancer after a negative hrHPV DNA test observed in screened cohorts 9 -- 2.1.5. Age to start HPV screening 10 -- 2.1.6. Triage algorithms 11 -- 2.2. ORGANISATION OF THE CERVICAL SCREENING IN BELGIUM 12 -- 2.2.1. Organisation in general 12 -- 2.2.2. Quality control of cytology 12 -- 2.2.3. Quality control of HPV 13 -- 2.3. CERVICAL SCREENING IN BELGIUM 13 -- 2.3.1. Introduction 13 -- 2.3.2. Consumption based on IMA data 14 -- 2.3.3. General cytological and HPV results 15 -- 2.3.4. Cyto-virological relation 18 -- 2.3.5. Cytohistological relation 20 -- 2.4. COST IMPLICATIONS 21 -- 2.4.1. Introduction 21 -- 2.4.2. Results 22 -- 2.4.3. Discussion and conclusion 23 -- 3. KEY POINTS AND RECOMMENDATIONS 23 -- 3.1. KEY POINTS 23 -- RECOMMENDATIONS 24 -- REFERENCES 25 Link for e-copy: https://doi.org/10.57598/R238Cs Format of e-copy: PDF (470 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3499 Copies(0)
Status No copy Chronic Fatigue Syndrome / Sabine Stordeur / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
Chronic Fatigue Syndrome : diagnosis, treatment and care organization - appendices [printed text] / Sabine Stordeur, Author ; Nancy Thiry, Author ; Marijke Eyssen , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2008 . - 75 p. : ill. ; 30 cm.. - (KCE Reports B. Health Services Research (HSR); 88S) .
ISSN : D/2008/10.273/60 : 0 €
Etude nr 2007-32-04
Languages : English (eng) French (fre)
Descriptors: Classification
WB 146 Asthenia. Cachexia. Fatigue
Indexation
2007-32-04 ; Developed Countries ; Diagnosis ; Evidence-Based Medicine ; Fatigue Syndrome, Chronic ; Health Services Research ; R88Link for e-copy: https://doi.org/10.57598/R88S Format of e-copy: .PDF (470 KB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1618 Copies(0)
Status No copy Chronisch Vermoeidheidssyndroom: / Sabine Stordeur / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
Chronisch Vermoeidheidssyndroom: : diagnose, behandeling en zorgorganisatie [printed text] / Sabine Stordeur, Author ; Nancy Thiry, Author ; Marijke Eyssen , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2008 . - ix, 125 p. : ill. ; 30 cm.. - (KCE Reports A. Health Services Research (HSR); 88A) .
ISSN : D/2008/10.273/58 : 0 €
Studie nr 2007-32-04
Languages : Dutch (dut) English (eng)
Descriptors: Classification
WB 146 Asthenia. Cachexia. Fatigue
Indexation
2007-32-04 ; Developed Countries ; Diagnosis ; Evidence-Based Medicine ; Fatigue Syndrome, Chronic ; Health Services Research ; R88Link for e-copy: https://doi.org/10.57598/R88A Format of e-copy: .PDF (1.16 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1538 Copies(0)
Status No copy
[article] Convincing or confusing? : Economic evaluations of childhood pneumococcal conjugate vaccination [printed text] / Philippe Beutels, Author ; Nancy Thiry, Author ; Pierre Van Damme, Author . - 2007 . - 1355-1367.
Research Support, Non-U.S. Gov't
Review
Languages : English (eng)
in Vaccine > 25(2007)8 [02/09/2007] . - 1355-1367
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
Child, Preschool ; Economics ; Humans ; immunology ; Infant ; Journal Article ; Netherlands ; Peer Review ; Pneumococcal Infections ; Pneumococcal Vaccines ; prevention and control ; Vaccines ConjugateAbstract: We review 15 economic analyses of pneumococcal conjugate vaccines, published between 2002 and 2006, in terms of methodology, assumptions, results and conclusions. We found a great diversity in assumptions (eg, vaccine efficacy parameters, incidence rates for both invasive and non-invasive disease) mainly due to local variation in data and opinions. Accordingly, the results varied greatly, from total net savings to over euro 100,000 per discounted QALY gained. The cost of the vaccination program (determined by price per dose and schedule (4 or 3 doses, or fewer)), and likely herd immunity impacts are highly influential though rarely explored in these published studies. If the net long-term impact (determined by a mixture of effects related to herd immunity, serotype replacement, antibiotic resistance and cross reactivity) remains beneficial and if a 3-dose schedule confers near-equivalent protection to a 4-dose schedule, the cost-effectiveness of PCV7 vaccination programs can be viewed as attractive in developed countries. Link for e-copy: http://tiny.cc/aalwe Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1767 [article]Cost-effectiveness analysis of HPV vaccination of boys in Belgium / Nancy Thiry / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)
Cost-effectiveness analysis of HPV vaccination of boys in Belgium [printed text] / Nancy Thiry, Author ; Sophie Gerkens , Author ; Justien Cornelis , Author ; Vicky Jespers , Author ; Germaine Hanquet, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2019 . - 107 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 308) .
ISSN : D/2019/10.273/13 : € 0,00
Languages : English (eng)
Descriptors: Indexation
2017-04 ; Costs and Cost Analysis ; Female ; Male ; Papillomavirus Infections ; Papillomavirus Vaccines ; R308 ; Technology Assessment, Biomedical
Classification
QZ 204 Precancerous conditions. Tumor virus infectionsContents note: LIST OF FIGURES 4 -- LIST OF TABLES .5 -- LIST OF ABBREVIATIONS 7 -- SCIENTIFIC REPORT .9 -- 1 BACKGROUND .9 -- 1.1 HPV INFECTION AND DISEASE .9 -- 1.2 THE HPV VACCINES 10 -- 1.2.1 Cervarix .11 -- 1.2.2 Gardasil .11 -- 1.2.3 Gardasil 9 .12 -- 2 HPV VACCINATION IN BELGIUM 12 -- 2.1 RECOMMENDATIONS OF HPV VACCINATION 12 -- 2.2 ORGANISATION AND FUNDING 13 -- 2.2.1 NIHDI reimbursement 13 -- 2.2.2 Vaccination programmes .14 -- 2.3 VACCINE UPTAKE 14 -- 3 RESEARCH QUESTIONS .15 -- 4 BURDEN OF HPV DISEASES IN BELGIUM 17 -- 4.1 METHODS 17 -- 4.2 HPV PREVALENCE IN BELGIUM OR IN SIMILAR SETTINGS 17 -- 4.3 BURDEN OF HPV-RELATED CANCERS .18 -- 4.3.1 Cervical cancer .22 -- 4.3.2 Anal cancers 22 -- 4.3.3 Vulvar cancer .22 -- 4.3.4 Vaginal cancer 23 -- 4.3.5 Penile cancer .23 -- 4.3.6 Oropharyngeal cancers .24 -- 4.4 BURDEN OF ANOGENITAL WARTS 25 -- 4.5 OTHER COMPLICATIONS OF HPV INFECTION .26 -- 4.6 GENDER DIFFERENCES IN HPV-RELATED DISEASES 26 -- 5 VACCINE EFFICACY AND SAFETY 27 -- 5.1 METHODS 27 -- 5.2 VACCINE EFFICACY 27 -- 5.2.1 Cervical cancers 29 -- 5.2.2 Anal cancer .31 -- 5.2.3 Vulvar and vaginal cancers .32 -- 5.2.4 Penile cancer .33 -- 5.2.5 Oropharyngeal cancer 34 -- 5.2.6 Anogenital warts 35 -- 5.2.7 Additional results for HPV9 .36 -- 5.3 BRIDGING STUDIES 36 -- 5.4 CROSS-PROTECTION 36 -- 5.5 DURATION OF PROTECTION 37 -- 5.6 EFFICACY OF SHORTER SCHEDULE .37 -- 5.7 COMPARISON ACROSS VACCINES .38 -- 5.8 VACCINE SAFETY .38 -- 6 HERD EFFECTS OF HPV VACCINATION 39 -- 6.1 METHODS 39 -- 6.2 SYSTEMATIC REVIEWS 39 -- 6.3 AUSTRALIA 40 -- 7 HPV VACCINATION OF MALES IN OTHER INDUSTRIALISED COUNTRIES 41 -- 7.1 BOYS .41 -- 7.2 MEN HAVING SEX WITH MEN 44 -- 8.1 METHODS 45 -- 8.2. Technical characteristics, vaccine costs and diseases modelled 46 -- 8.2.2 Vaccine efficacy and duration of protection 48 -- 8.2.3 Outcomes considered 50 -- 8.2.4 Disease burden and HPV attribution fraction .50 -- 8.3.1 Criteria 55 -- 8.3.2 Results 55 -- 8.4.1 What is the cost-effectiveness universal (girls and boys) versus girl-only HPV vaccination for the EMA+ indications? 59 -- 8.4.2 What is the cost-effectiveness of universal (girls and boys) versus girl-only HPV vaccination for all HPV-related diseases? 63 -- 8.4.3 Is extending HPV vaccination to boys more cost-effective than increasing the vaccine uptake in girls? 66 -- 8.4.4 If universal (girls and boys) vaccination is opted for, which vaccine is cost-effective? 68 -- 8.4.5 What is the cost-effectiveness of universal (girls and boys) versus girl-only vaccination using low vaccine prices? 69 -- 8.4.6 What is the impact of the vaccine duration of protection on the incremental costeffectiveness ratio? .70 -- 9 DISCUSSION 72 -- 9.1 CLINICAL ASPECTS .72 -- 9.2 ECONOMIC ASPECTS 73 -- 9.3 OTHER ASPECTS 74 -- 9.4 LIMITATIONS 75 -- 9.5 CONCLUSIONS 76 -- APPENDICES 77 -- REFERENCES .94 Link for e-copy: https://doi.org/10.57598/R308C Format of e-copy: PDF (3,02 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4509 Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkCost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium / Yvres Horsmans / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkCost-effectiveness of human papillomavirus vaccination in Belgium / Nancy Thiry in International Journal of Technology Assessment in Health Care, 25(2009)2 ([04/01/2009])
PermalinkCost Effectiveness of Implantable Cardioverter-Defibrillators for Primary Prevention in a Belgian Context / Mattias Neyt in Applied Health Economics and Health Policy, 6(2008)1 ([10/01/2008])
PermalinkLe Défibrillateur Cardiaque Implantable: un rapport d'évaluation de technologie de santé / Hans Van Brabandt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)
PermalinkDo innovative medicines against cancer always have a real added value? / Mattias Neyt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2021)
PermalinkDrempelwaarden voor kosteneffectiviteit in de gezondheidszorg / Irina Cleemput ; Mattias Neyt ; Nancy Thiry ; Chris De Laet ; Mark Leys / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
Permalink[Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium] / Christoph Schwierz / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkEconomic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
PermalinkEconomic evaluations of pneumococcal vaccination strategies in adults / Nancy Thiry in Acta Clinica Belgica, 60(2005)6 ([11/02/2005])
Permalink